Merck's Keytruda & Padcev Combo Gets EU Nod for Urothelial Carcinoma

Merck (MRK) announced that the European Commission has granted approval to a combination regimen of its blockbuster PD-L1 inhibitor, Keytruda, for expanded use in a type of bladder cancer. The approval is for Keytruda in combination with Astellas/Pfizer’s (PFE) antibody-drug conjugate Padcev for the first-line treatment of adult patients with unresectable or metastatic urothelial carcinoma, a type of bladder cancer.The approval was expected as, in July, the Committee for Medicinal Products for Human Use of ...